VW Bus Back as EV

"With Li-ion battery pack, charging takes less than one hour."

The Volkswagen microbus, which made its debut in the 1950s, has made a comeback at the Geneva Motor Show in the form of an electric compact van. In a reinterpretation of the original, which was dubbed the 'Bulli' on its home German market, the new Bulli is powered by an 85 KW electric motor with a range of up to 300 km., according to VW.

The motor is powered by a lithium-ion battery pack with a maximum storage capacity of 40 kWh. When the Bulli's battery is charged at an electric refueling station specially designed for electric vehicles, the charging process takes less than one hour.

Like the Samba bus before it, the Geneva Bulli comes in two-tone white and red paintwork. But in this case, the Bulli has an electric motor located forward of the front axle and front-wheel drive. Here it is a compact integral drive whose primary components are an E-motor, high-voltage pulse inverter and AC/DC converter for the 12-vVolt electrical system.

Acceleration from 0–100 km./hr. takes 11.5 seconds with a top speed of 140 km./hr.

In addition the new Bulli concept can also incorporate petrol and diesel direct-injection engines as alternative drives.

The new edition is 3.99m long, 1.75m wide and 1.70m tall. The wheelbase measures 2.62m.

In keeping with the Volkswagen design DNA, there is a horizontal layout of the narrow dual headlights with L-shaped LED daytime running lights and turn indicators implemented as LEDs arranged in an inverted L shape at each outer corner.

Concealed in the sandwiched floor behind the sills is the 1,450-kilo. lithium-ion battery.

After presenting a similar lifestyle concept study 10 years ago, this one appears close to serial production with a possible 2014 launch.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.